SecBot SecBot

RARE drug pipeline

$15.90
−1.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.7%
1-day, median of 14 events
IV rank
No data
No current options data
Rated drugs
2
1 bearish · 1 neutral
Phase 3 trials
4
1 with results posted

Upcoming catalysts

1 dated
  1. Jan 2027
    UX143
    Phase 3 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and launched commercially as of September 2026.

FAYUVI rebisufligene etisparvovec Updated Nov 5

What to watch

With the approval binary behind it, FAYUVI's investor focus shifts to commercial execution: Q4 2026 and early 2027 revenue disclosures, payer reimbursement decisions, and the number of patients dosed. The stock's 52-week range ($12.73-$39.89) and recent cost-cutting plan suggest the market is pricing in execution risk. Watch for early revenue signals from the Q4 2026 earnings report and any updates on treatment center activations.

Bull case
  • First and only FDA-approved treatment for Sanfilippo syndrome type A, a fatal childhood disease with no prior disease-modifying options, giving it a monopoly position in an ultra-rare indication with 3,000-5,000 patients in the US.
  • List price of $3.95 million per one-time dose positions it as a potential blockbuster if even a small fraction of eligible patients are treated, and the company received a $203 million Priority Review Voucher upon approval.
  • Ultragenyx is targeting GAAP profitability in 2027, with Q3 2026 total revenue of $173 million, and FAYUVI plus the earlier gene therapy GENGLYCOS represent new revenue streams beyond the established CRYSVITA franchise.
Bear case
  • At $3.95 million list price, commercial adoption faces significant payer access hurdles; ultra-rare gene therapies often see slow uptake as insurers negotiate outcomes-based contracts and treatment centers must be certified.
  • The drug was rejected by the FDA in 2025 due to manufacturing problems, highlighting manufacturing risk for complex gene therapies, and the open-label single-arm trial design (no placebo control) leaves some efficacy uncertainty.
  • Ultragenyx recently cut 20% of its workforce, discontinued the GTX-102 Angelman syndrome program, and saw multiple analyst downgrades in September 2026 (JP Morgan, William Blair, Evercore, Baird), reflecting pipeline and commercial concerns.
▼ bearish
Impact
PhasePhase 3 (completed)
Time to marketUncertain. The drug failed its Phase 3 primary endpoints. Ultragenyx and partner Mereo are in discussions with FDA, EMA, and UK regulators about a potential path forward, particularly in pediatric patients. No regulatory submission has been announced and no PDUFA date exists. Regulatory feedback is expected by year-end 2026.

UX143 setrusumab Updated Nov 5

What to watch

Watch for regulatory feedback from FDA/EMA discussions expected by year-end 2026, which will determine whether setrusumab has a viable path to approval despite the primary endpoint miss. The key question is whether regulators will accept bone mineral density improvements as a surrogate for fracture reduction in pediatric OI patients. A negative regulatory signal would likely end the program; a positive signal could open a narrow approval pathway.

Bull case
  • Setrusumab was spared from Ultragenyx's November 2026 restructuring that cut 20% of staff and axed other pipeline programs, signaling the company still sees potential value
  • The drug achieved strong, statistically significant improvements in bone mineral density (a key secondary endpoint) in both Phase 3 studies, and post-hoc analyses presented at ASBMR 2026 showed meaningful fracture benefits
  • FDA granted Breakthrough Therapy Designation in October 2024, which could facilitate a more flexible regulatory review even after the primary endpoint miss
Bear case
  • Both Phase 3 trials (Orbit and Cosmic) failed their primary endpoints of reducing annualized clinical fracture rate, the most clinically meaningful metric for OI patients
  • Ultragenyx stock lost ~43-45% of its value on the December 29, 2025 readout, erasing over $1 billion in market cap
  • Multiple analysts downgraded the stock (JP Morgan, William Blair, Evercore, Baird) and several trimmed price targets following the failure

Other drugs in filings and trials

no drug report yet
  • DTX401 Last: PDUFA decision · Aug 23, 2026
  • DOJOLVI Last: Approval · Jun 30, 2020
  • MEPSEVII Last: Approval · Nov 15, 2017
  • GTX-102 3 trials
  • Oral prednisolone 1 trial
  • Triheptanoin oil 1 trial

Past FDA events & how the stock moved

14 events
DateDrugEvent1 day5 days
Sep 19, 2026FAYUVIPDUFA decision+1.0%−0.1%
Aug 23, 2026DTX401PDUFA decision−0.4%−0.8%
Apr 1, 2026FAYUVIBLA filed+7.2%+14.1%
Mar 31, 2026FAYUVIBLA filed+11.0%+19.9%
Feb 28, 2026FAYUVIRefuse to file−1.6%−9.2%
Feb 24, 2026FAYUVIComplete response letter+1.8%−1.9%
Feb 1, 2026DTX401Priority review+2.9%+2.6%
Feb 1, 2026DTX401BLA filed+2.9%+2.6%
Jan 31, 2026FAYUVIBLA filed+2.9%+2.6%
Jan 1, 2026FAYUVIBLA filed+2.6%+0.9%
Jan 1, 2026FAYUVIRefuse to file+2.6%+0.9%
Feb 1, 2025FAYUVIPriority review+0.9%+5.4%
Jun 30, 2020DOJOLVIApproval+14.9%+22.2%
Nov 15, 2017MEPSEVIIApproval+5.9%+7.4%

Clinical trials

6 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
UX143Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaPhase 3Active not recruiting6Jan 2027
GTX-102A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)Phase 2Terminated55Oct 30, 2026
GTX-102Long-term Extension of GTX-102 in Angelman SyndromePhase 3Terminated66Oct 30, 2026
GTX-102Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Phase 3Terminated129Jul 10, 2026
Oral prednisoloneA Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)Phase 3Completed · results52Feb 20, 2024
Triheptanoin oilA Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's DiseasePhase 2Completed100Dec 3, 2019